

Docket No.: 71417/55062

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Gravereaux, et al. EXAMINER: Not Yet Assigned

SERIAL NO.: 09/970,088 GROUP: 1614

FILED: October 2, 2001

FOR: USE OF LYMPHANGIOGENIC AGENTS TO TREAT LYMPHATIC

DISORDERS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 31, 2003.

Rv.

Sharon Bizokas

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

SEARCH REPORT INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

U.S.S.N.: 09/970,088 Inventors: Gravereaux, et al. Filed: October 2, 2001 Page 2 of 4

II.	<u>COPIES</u>											
	a. <u>X</u>	Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed. Copies of U.S. patents are no longer required										
	b	This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application Serial No, filed on The following references were submitted to, and/or cited by, the Office in the prior application (s) and, therefore, are not required to be provided in this application.										
III.	CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)											
	a. <u>X</u>	Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).										
	b	A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:										
	c. <u>X</u>	The following additional information is provided for the Examiner' consideration:										
		X Copy of PCT Search Report. U.S. Patent 6,040,157 (March 21, 2000) (Hu et al.) was previously listed on the Form PTO-1449 filed with the Search Report IDS on January 22, 2003.										
	FEES											
IV.	THIS IDS IS (check one b	BEING FILED UNDER 37 C.F.R. § 1.97(b) pox)										
	a	within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1]. No fee or certification is required.										
	b	within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2). No fee or certification is required.										

U.S.S.N.: 09/970,088 Inventors: Gravereaux, et al. Filed: October 2, 2001

Page 3 of 4

c. X Before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e)below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): (check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

a. ___ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. . § 1.17(p).

or

b. X See the certification below. No fee is required.

VI. <u>CERTIFICATION UNDER 37 C.F.R. § 1.97(e)</u> (check only one box)

The undersigned hereby certifies that

- a. X each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ___ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

U.S.S.N.: 09/970,088 Inventors: Gravereaux, et al. Filed: October 2, 2001

Page 4 of 4

Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.

X No fee is required.

The fee in the amount of \$180.00 is enclosed herewith.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule, with a petition if necessary, and charge the appropriate fee to Deposit Account No. **04-1105**.

Respectfully submitted,

Date: October 31, 2003

Kathryn A. Piffat, Ph.D. (Reg. No.: 34,901) Intellectual Property Practice Group of

EDWARDS & ANGELL, LLP

P.O. Box 9169

Boston, Massachusetts 02209

Phone: (617) 439-4444 Fax: (617) 439-4170

Customer No. 21874

BOS2_351817.1

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT ON O 3 2003					TY DOCKET NO.	SERIAL NO.				
					71417/55062		09/970,088			
					APPLICANT(S): Gravereaux et al.					
					FILING DATE: ART UNIT: October 2, 2001 1614					
MARK	UEELL	UNITED STA	ATES PATEN	T DO	CUMENTS					
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS	FIL. DATE IF APPR		
	AA	5,776,755	07/07/98	Al	italo et al.	435	194	11/14/94		
	AB	5,840,693	11/24/98	Eri	iksson et al.	514	12	03/01/96		
	AC	6,020,473	02/01/00	Keyt et al.		536	23.1	12/05/95		
		FOREI	GN PATENT DO	CUME	NTS					
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB CLASS	TRAN YES/NO		
				i						
01	THER DOC	CUMENTS (INCLUDING AU	UTHOR, TITLE	3, DA	TE, PERTINENT	PAGES,	ETC.)			
	CA Sharar et al., "Ischemia Reperfusion Injury in the Rabbit Ear Is Reduced by Both Immediate and Delayed CD18 Leukocyte Adherence Blockade", The Journal of Immunology, 153:2234-2238 (1994)									
	CB Stepnick et al., "Effects of Tumor Necrosis Factor α and Vascular Permeability Factor on Neovascularization of the Rabbit Ear Flap", Arch Otolaryngol Head Neck Surg., 121:667-672 (1995)									
							-			
Examiner:			_		Date:					